Marathon Sells Muscular-Dystrophy Drug to PTC After Pricing Scrutiny – Wall Street Journal (subscription)

Posted: Published on March 19th, 2017

This post was added by Dr Simmons


Wall Street Journal (subscription)
Marathon Sells Muscular-Dystrophy Drug to PTC After Pricing Scrutiny
Wall Street Journal (subscription)
Marathon Pharmaceuticals LLC has struck a deal to sell its muscular-dystrophy treatment to PTC Therapeutics Inc., one month after Marathon's $89,000 price tag for the drug spurred an outcry from patient advocates and federal lawmakers. Marathon will ...
PTC Therapeutics Announces Agreement to Acquire Emflaza for the Treatment of Duchenne Muscular Dystrophy in USPR Newswire (press release)
PTC Therapeutics to Acquire Emflaza for Treatment of DMD in the USMuscular Dystrophy News
Why Orphan Drug Act needs reformHot Springs Sentinel
Healthcare Finance News -Stock Market Daily -Yahoo Finance
all 58 news articles »

Read the original here:
Marathon Sells Muscular-Dystrophy Drug to PTC After Pricing Scrutiny - Wall Street Journal (subscription)

Related Posts
This entry was posted in Muscular Dystrophy Treatment. Bookmark the permalink.

Comments are closed.